and urine are well documented, but there are very little data on natural levels in saliva, a biological matrix increasingly used for drug testing. We measured endogenous GHB concentrations in 120 unpaid volunteers who also provided anonymous epidemiological data. Samples were analyzed using a rapid and reliable method, utilizing liquid-liquid extraction, silylderivatization, and gas chromatographic-mass spectrometric analysis. One sample, between the lower limit of quantitation (0.2 mg/L) and limit of detection (0.1 mg/L), was split to 0.15 mg/L for statistical purposes. Salivary GHB concentrations ranged from 0.15 to 3.33 mg/L (mean = 1.29; median = 1.13). Statistical analysis using the Mann-Whitney test indicated that endogenous GHB concentrations in saliva were not significantly affected by age, gender, medical conditions, use of medications, and recent food/drink consumption. Interpreting GHB concentrations in biological samples poses difficulties because of its endogenous presence and rapid elimination, and this is true for saliva as well as blood and urine. However, saliva has the merit of being easy to collect by law enforcement personnel.
Introduction
Evaluating the significance of γ-hydroxybutyric acid (GHB) concentrations in biological samples poses difficulties due to its endogenous presence and rapid elimination. Following ingestion of 1-5-g doses, GHB levels have been reported to fall to near endogenous concentrations after 8 h or less in blood and 12 h or less in urine (1) (2) (3) (4) . As a result, biological specimens for toxicological analysis need to be collected as soon as possible following suspected GHB intake and care needs to be taken when interpreting the analytical results. Numerous studies have established reference ranges for endogenous GHB concentrations in blood (Table I ) and urine (Table II) . The reference ranges have given rise to the suggestion, in the absence of any clear explanation of the mathematical rationale, that there should be cutoff levels of 5 mg/L for blood and 10 mg/L for urine, below which it would not be possible to state whether the GHB detected was of endogenous or exogenous origin (5) (6) (7) (8) (9) (10) (11) (12) (13) . In a recent work (14) , the authors suggested a new, lower cutoff for both blood and urine (4 and 6 mg/L, respectively) to avoid false-negative results. The use of saliva as a matrix for drug testing is well established (15) (16) (17) (18) (19) (20) , and it is frequently used by substance misuse services and by the police. However, there are few published studies of GHB analysis in saliva (21) (22) (23) (24) (25) , with one attempt to establish the range of endogenous GHB concentrations in saliva from only 20 volunteers (24) . To fill this gap in knowledge of endogenous GHB levels in saliva, we undertook a population study of salivary GHB concentrations, with assessment of the potential influence of epidemiological factors. For this purpose, a reliable and fast gas chromatography-mass spectrometry (GC-MS) method for the analysis of GHB in saliva was developed and validated.
Abstract

Materials and Methods
Saliva samples were collected from 120 unpaid volunteers (75 female; 45 male), ranging in age from 17 to 52 years (mean = 24; median = 21). All participants provided informed consent prior to sample collection and completed a short survey to collect information on gender, age, ethnic origin, medical conditions, use of medications within 48 h prior to collection, and recent food or drink intake. Specimens were donated anonymously, and survey results were linked to samples by random number assignment. Saliva was collected using Salivette ® (Sarstedt, Leicester, U.K.) devices according to the manufacturer's instructions, and following collection, the samples were centrifuged for 5 min (at 3600 rpm) and analyzed immediately or stored without preservative at -22.5°C until analysis.
Working solutions of 10 mg/L GHB and GHB-d 6 were prepared in methanol from Na-GHB and GHB-d 6 sodium salt, both 1000 mg/L in methanol (LGC, Teddington, U.K.). A saliva sample (300 µL) was fortified with 80 µL of internal stan- dard (10 mg/L GHB-d 6 ) and 1 mL of saturated ammonium chloride buffer; then extracted with 5 mL of ethyl acetate. Following centrifugation (5 min at 3600 pm), the upper organic layer was transferred to a glass vial and evaporated to dryness under nitrogen at room temperature. BSTFA with 1% TMCS derivatizing agent (30 µL) was added; the sample was mixed and then incubated at 60°C for 30 min. After cooling the samples were transferred to autosampler vials for GC-MS analysis. GC-MS analysis was performed on a Agilent Technologies 7890A GC (Agilent Technologies, Stockport, U.K.) equipped with an HP-5MS capillary column (30 m × 0.25-mm i.d., 0.25-µm film thickness). An Agilent 7683B series injector was used for sample injection. Data acquisition was by MSD ChemStation E.02.00.493 software. Split injection (20:1) was applied with an injection volume of 2 mL, injection temperature 250°C, and detector temperature 230°C. The temperature gradient started at 80°C ramping to 150°C (10°C/min for 1 min), then ramping to 300°C (40°C/min for 2 min); total run time 13.75 min; solvent delay 5.8 min. An Agilent Technologies 5975C massselective detector operating in the electron ionization and selective ion monitoring mode (SIM) was used for quantitative analysis of GHB and GHB-d 6 . The following two ions were monitored for each compound (22, 24) : GHB-diTMS m/z 233 and 234; GHB-d 6 -diTMS: m/z 239 and 240 (underlined ions were used for quantification). GHB-diTMS Rt was 6.27 min and GHB-d 6 -diTMS 6.22 min.
A calibration curve (n = 5) was obtained by preparing standards with OraFlx negative synthetic saliva (LGC) containing 0.2, 0.5, 1.0, 2.0, and 5.0 mg/L of spiked GHB. The calibration curves were based on ratios of the integrated area of the m/z 233 molecular ion of GHB to the integrated area of the m/z 239 molecular ion of GHB-d 6 (Figures 1 and 2) . Standard curves for GHB in synthetic saliva were linear in the range of 0.2-5.0 mg/L, with an R² value of 0.9986.
Survey saliva samples were analyzed in triplicate for the determination of endogenous GHB (Figure 3) . Intra-and interday accuracy and precision were determined using quality control samples of synthetic saliva spiked at 0.5 and 2 mg/L with GHB. These samples were analyzed in five replicates on three different days. Intraday (n = 5) precision (%RSD) and accuracy (%Bias) were 5.08 and 5.6 for the low quality control (LQC), and 2.42 and -0.2 for the high quality con- trol (HQC). Interday (n = 15) precision (%RSD) and accuracy (%Bias) were 4.14 and 1.33 for the LQC and 0.75 and 0.67 for the HQC, satisfying the acceptance criteria for precision (within 15% RSD) and accuracy (bias within ±15% of the accepted reference value) (26) . The limit of detection (LOD) and lower limit of quantification (LLOQ) were determined by estimating the minimum concentration that would produce a signal-to-noise ratio of 3 and 10, respectively. The LOD was 0.1 mg/L and the LLOQ was the first point on the calibration curve, 0.2 mg/L. No interfering peaks were observed in a series of 20 blank human saliva samples analyzed. Derivatives were stable for at least 24 h at 5°C, and saliva samples were stable for 30 days at -22.5°C
Results and Discussion
All samples contained measurable amounts of GHB above the LOD (0.1 mg/L), with only one sample yielding a GHB concentration between the LLOQ and LOD. The GHB concentration for this sample was set to a midpoint of 0.15 mg/L for statistical comparisons. Endogenous GHB concentrations in all 120 samples ranged from 0.15 to 3.33 mg/L (mean = 1.29 mg/L; median = 1.13 mg/L). The distribution of endogenous GHB concentrations for the 120 samples is shown in Figure 4 . The endogenous GHB concentrations reported in this study are similar to those reported in one previous study (24) , but the range of salivary GHB concentration we observed is slightly wider, as might be expected given our larger study number (120 vs. 20). The observed mean and median concentrations in saliva are higher than those previously reported in blood (11) (12) (13) (14) .
The age of participants ranged from 17 to 52 years (mean = 24 years). For comparison, participants were divided into three groups (to create the appropriate number for statistical analysis) based on age: 17 to 20, 21 to 29, and 30 to 52 years.
Eleven participants did not state if they had any medical conditions. Four individuals did not state whether or not they had used medications within 48 h prior to collection. One participant failed to answer the question on recent food and drink consumption. Statistical analysis was carried out using the Mann-Whitney test (95% confidence interval; α = 0.05; twotailed) for significant trends in endogenous GHB concentration between different groups. Factors examined were gender (females vs. males), age (17-20 vs. 21-29, 17 -20 vs. 30-52, and 21-29 vs. 30-52), use of medications (use of medications vs. no use of medications), presence of medical conditions (no medical conditions vs. medical conditions) and time since food or drink intake prior to sample collection (< 1 h vs. 1-2 h, < 1 h vs. > 2 h, and 1-2 h vs. > 2 h) ( Table III) . The between-group variations in endogenous GHB concentration that we observed were not statistically significant, with a p value of greater than 0.05 in all instances.
Conclusions
Interpretation of GHB concentrations in biological fluids is problematic as a result of its endogenous presence and rapid elimination from the body. Similar interpretive issues will always arise whichever matrix is used for analysis. After a single dose of GHB, observed concentrations in saliva parallel those in blood over time but at a much lower concentration, and for this reason, blood has been recommended in preference to saliva for forensic analysis (22) . However, this recommendation is based upon the assumption that both blood and saliva could be sampled at the same moment. In practice, the requirement of a blood draw may cause a delay in sampling because of the need for trained personnel, whereas the collection of a saliva sample can be carried out quickly, easily, and noninvasively by personnel with minimal training, which is a significant practical advantage. The rapid and reliable method for GHB analysis we used requires only 300 µL of sample for quantification in saliva. The range of endogenous salivary GHB concentrations documented in this study should aid in the interpretation of the analytical results.
In our view, the data do not permit simple justification for a cutoff level. Some of the cutoff levels suggested from other authors appear to be based on an arbitrary decision without a transparent rationale. 
